Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhotoCure Basal Cell Carcinoma Phototherapy Has “Niche” Market Potential

Executive Summary

PhotoCure's methyl aminolevulinate could be approved as part of a "niche" basal cell carcinoma phototherapy regimen for patients who are intolerant to other treatments, an FDA advisory committee said in voting against a broader indication

You may also be interested in...



PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA

PhotoCure/Galderma expect to launch their actinic keratosis phototherapy in "several weeks" following the approval of an alternate tradename

PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA

PhotoCure/Galderma expect to launch their actinic keratosis phototherapy in "several weeks" following the approval of an alternate tradename

PhotoCure Metvix approval

FDA will finish reviewing the Metvix (methyl amniolevulinate) NDA for actinic keratoses no later than July 27, PhotoCure says. An FDA advisory committee voted against approval of the phototherapy for the first-line treatment of basal cell carcinoma (1"The Pink Sheet" Sept. 15, 2003, p. 20). The NDA was later deemed "approvable," and PhotoCure submitted a safety update...

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel